Antibody Therapeutics Market Key Players, Price, Top Manufacturers And Forecast To 2028

The global antibody therapeutics market in terms of revenue was estimated to be worth $247.3 billion in 2023 and is poised to reach $479.0 billion by 2028
Antibody Therapeutics Market [https://www.marketsandmarkets.com/Market-Reports/antibody-therapeutics-market-178852478.html?utm_source=ABnewswire+&utm_campaign=Paid&utm_content=Referral] in terms of revenue was estimated to be worth $247.3 billion in 2023 and is poised to reach $479.0 billion by 2028, growing at a CAGR of 14.1% from 2023 to 2028 according to a new report by MarketsandMarkets. The growing advancements in antibody engineering, the growing demand for oncology antibody therapeutics and the increasing clinical pipeline focus on antibody therapeutics are the factors supporting the growth of this market.

Download PDF Brochure @ [https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=178852478&utm_source=ABnewswire+&utm_campaign=Paid&utm_content=Referral]

Browse in-depth TOC on "Antibody Therapeutics Market"

313 - Tables

51 - Figures

306 - Pages

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the antibody therapeutics market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.

Inquiry Before Buying: [https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=178852478&utm_source=ABnewswire+&utm_campaign=Paid&utm_content=Referral]

Key Market Players of Antibody Therapeutics Industry:

The market for antibody therapeutics market is consolidated, with key players strategizing to capture the market. Prominent players in the antibody therapeutics market are F. Hoffmann-La Roche Ltd. (Switzerland), AbbVie Inc. (US), Johnson & Johnson (US), Merck KGaA (Germany), Bristol-Myers Squibb (US), AstraZeneca (UK), Sanofi (France), Regeneron Pharmaceuticals, Inc. (US), Novartis AG (Switzerland), Amgen, Inc. (US), Biogen Inc. (US) among others.

Antibody Therapeutics Market Dynamics:

Drivers:

1. Growing advancements in antibody engineering

Restraints:

1. Stringent regulatory approval process

Opportunities:

1. Increasing collaboration of pharmaceutical companies with CROs, CDMOs and academic institutions

Challenge:

* Complexities in manufacturing processes

All the market segments have been divided for the Antibody Therapeutics market to forecast revenue and analyze trends in each of the following submarkets:

By Format

* Monoclonal antibody
* Polyclonal antibody therapy
* Bispecific antibody
* Antibody fragment
* Other antibody formats

By Disease Areas

* Autoimmune & inflammatory diseases
* Oncology
* Hematology
* Infectious diseases
* Osteology
* Immunology
* Neurology
* Other disease areas

By Route of Administration

* Intravenous
* Subcutaneous
* Other routes of administration

By Source

* Human
* Humanized
* Chimeric
* Other sources

By End User

* Hospitals
* Long-term care facilities
* Other end users

By Region

* North America
* Europe
* Asia Pacific (APAC)
* Latin America
* Middle East

Recent Developments of Antibody Therapeutics Industry

* In October 2023, F. Hoffmann-La Roche Ltd. entered into a definitive agreement to acquire Televant. Through this agreement, Roche received the development, manufacturing and commercialization rights in the US and Japan for Telavant's RVT-3101, a novel TL1A directed antibody.
* In January 2023, AbbVie Inc. and Immunome, Inc. entered into strategic collaboration to identify up to 10 novel target-antibody pairs leveraging Immunome's Discovery Engine.

Get 10% Free Customization on this Report: [https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=178852478&utm_source=ABnewswire+&utm_campaign=Paid&utm_content=Referral]

About MarketsandMarkets Trademark :

MarketsandMarkets Trademark has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets Trademark is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore Trademark (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets Trademark Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=antibody-therapeutics-market-key-players-price-top-manufacturers-and-forecast-to-2028]
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=178852478



This release was published on openPR.